BMEA
Biomea Fusion, Inc. Common Stock
stockNASDAQ
biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients' needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.66 | 2026-11-02 | -7.91% | 0.178 |
| 1M | 1.42 | 2026-10-09 | -57.20% | 1.000 |
| 3M | 1.27 | 2026-08-10 | -52.15% | 1.015 |
| 6M | 1.54 | 2026-05-08 | -60.54% | 1.182 |
| 1Y | 1.37 | 2025-11-10 | -55.64% | 1.376 |
| 2Y | 8.18 | 2024-11-08 | -92.57% | — |
| 5Y | 11.15 | 2021-11-09 | -94.55% | 1.120 |
Biomea Fusion, Inc. Common Stock (NASDAQ:BMEA) stock price today is $0.61, and today's volume is 279,627. BMEA is up 7.216% today. The 30 day average volume is 2.22M. BMEA market cap is $44.05M with 72.48M shares outstanding.